Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Savolitinib (AZD6094, HMPL-504) has been demonstrated to inhibit the growth of tumors in a series of preclinical disease models, selectively for those tumors with aberrant c-Met signaling. Phase I dose escalation studies were initiated in Australia a...